Literature DB >> 22266856

A general method to derive robust organ-specific gene expression-based differentiation indices: application to thyroid cancer diagnostic.

G Tomás1, M Tarabichi, D Gacquer, A Hébrant, G Dom, J E Dumont, X Keutgen, T J Fahey, C Maenhaut, V Detours.   

Abstract

Differentiation is central to development, while dedifferentiation is central to cancer progression. Hence, a quantitative assessment of differentiation would be most useful. We propose an unbiased method to derive organ-specific differentiation indices from gene expression data and demonstrate its usefulness in thyroid cancer diagnosis. We derived a list of thyroid-specific genes by selecting automatically those genes that are expressed at higher level in the thyroid than in any other organ in a normal tissue's genome-wide gene expression compendium. The thyroid index of a tissue was defined as the median expression of these thyroid-specific genes in that tissue. As expected, the thyroid index was inversely correlated with meta-PCNA, a proliferation metagene, across a wide range of thyroid tumors. By contrast, the two indices were positively correlated in a time course of thyroid-stimulating hormone (TSH) activation of primary thyrocytes. Thus, the thyroid index captures biological information not integrated by proliferation rates. The differential diagnostic of follicular thyroid adenomas and follicular thyroid carcinoma is a notorious challenge for pathologists. The thyroid index discriminated them as accurately as did machine-learning classifiers trained on the genome-wide cancer data. Hence, although it was established exclusively from normal tissue data, the thyroid index integrates the relevant diagnostic information contained in tumoral transcriptomes. Similar results were obtained for the classification of the follicular vs classical variants of papillary thyroid cancers, that is, tumors dedifferentiating along a different route. The automated procedures demonstrated in the thyroid are applicable to other organs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22266856     DOI: 10.1038/onc.2011.626

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  41 in total

1.  Down-Regulation of APTR and it's Diagnostic Value in Papillary and Anaplastic Thyroid Cancer.

Authors:  Ke Zhang; Cuilin Li; Jianqiu Liu; Zhi Li; Chao Ma
Journal:  Pathol Oncol Res       Date:  2018-12-11       Impact factor: 3.201

2.  The differences of regulatory networks between papillary and anaplastic thyroid carcinoma: an integrative transcriptomics study.

Authors:  Zongfu Pan; Lu Li; Yangyang Qian; Xinyang Ge; Xiaoping Hu; Yiwen Zhang; Minghua Ge; Ping Huang
Journal:  Cancer Biol Ther       Date:  2020-08-23       Impact factor: 4.742

3.  Identification and Validation of a Prognostic Signature for Thyroid Cancer Based on Ferroptosis-Related Genes.

Authors:  Yue Wang; Jing Yang; Shitu Chen; Weibin Wang; Lisong Teng
Journal:  Genes (Basel)       Date:  2022-06-01       Impact factor: 4.141

4.  Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors.

Authors:  Naris Nilubol; ZiQiang Yuan; Giulio F Paciotti; Lawrence Tamarkin; Carmen Sanchez; Kelli Gaskins; Esther M Freedman; Shugeng Cao; Jielu Zhao; David G I Kingston; Steven K Libutti; Electron Kebebew
Journal:  J Natl Cancer Inst       Date:  2018-09-01       Impact factor: 13.506

5.  Aberrant Activation of Notch Signaling Inhibits PROX1 Activity to Enhance the Malignant Behavior of Thyroid Cancer Cells.

Authors:  Dongwon Choi; Swapnika Ramu; Eunkyung Park; Eunson Jung; Sara Yang; Wonhyeuk Jung; Inho Choi; Sunju Lee; Kyu Eui Kim; Young Jin Seong; Mingu Hong; George Daghlian; Daniel Kim; Eugene Shin; Jung In Seo; Vicken Khatchadourian; Mengchen Zou; Wei Li; Roger De Filippo; Paul Kokorowski; Andy Chang; Steve Kim; Ana Bertoni; Tania Weber Furlanetto; Sung Shin; Meng Li; Yibu Chen; Alex Wong; Chester Koh; Jan Geliebter; Young-Kwon Hong
Journal:  Cancer Res       Date:  2015-11-25       Impact factor: 12.701

6.  Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.

Authors:  Jeffrey A Knauf; Kathleen A Luckett; Kuen-Yuan Chen; Francesca Voza; Nicholas D Socci; Ronald Ghossein; James A Fagin
Journal:  J Clin Invest       Date:  2018-08-20       Impact factor: 14.808

7.  Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers.

Authors:  Kathleen A Luckett; Jennifer R Cracchiolo; Gnana P Krishnamoorthy; Luis Javier Leandro-Garcia; James Nagarajah; Mahesh Saqcena; Rona Lester; Soo Y Im; Zhen Zhao; Scott W Lowe; Elisa de Stanchina; Eric J Sherman; Alan L Ho; Steven D Leach; Jeffrey A Knauf; James A Fagin
Journal:  Endocr Relat Cancer       Date:  2021-05-18       Impact factor: 5.900

8.  Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease.

Authors:  Eliseo Papa; Michael Docktor; Christopher Smillie; Sarah Weber; Sarah P Preheim; Dirk Gevers; Georgia Giannoukos; Dawn Ciulla; Diana Tabbaa; Jay Ingram; David B Schauer; Doyle V Ward; Joshua R Korzenik; Ramnik J Xavier; Athos Bousvaros; Eric J Alm
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

9.  Identification of key biomarkers for thyroid cancer by integrative gene expression profiles.

Authors:  Jinyi Tian; Yizhou Bai; Anyang Liu; Bin Luo
Journal:  Exp Biol Med (Maywood)       Date:  2021-04-25

10.  InSilico DB genomic datasets hub: an efficient starting point for analyzing genome-wide studies in GenePattern, Integrative Genomics Viewer, and R/Bioconductor.

Authors:  Alain Coletta; Colin Molter; Robin Duqué; David Steenhoff; Jonatan Taminau; Virginie de Schaetzen; Stijn Meganck; Cosmin Lazar; David Venet; Vincent Detours; Ann Nowé; Hugues Bersini; David Y Weiss Solís
Journal:  Genome Biol       Date:  2012-11-18       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.